Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

This publication has 29 references indexed in Scilit:

• Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
  The Lancet, 2001
• The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients
  Journal of Investigative Dermatology, 1999
• Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
  New England Journal of Medicine, 1997
• Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
  Nature Medicine, 1995
• Interleukin 1a, Tumor Necrosis Factor a, and Interferon ? in Psoriasis
  Archives of Dermatology, 1991
• Localization of Neutrophil-Activating Peptide-1/Interleukin-8-Immunoreactivity in Normal and Psoriatic Skin
  Journal of Investigative Dermatology, 1991
• In situ localization of interferons in psoriatic lesions
  Archives of Dermatological Research, 1989
• Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.
  Proceedings of the National Academy of Sciences, 1989
• Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques.
  The Journal of Experimental Medicine, 1988
• Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.
  The Journal of Experimental Medicine, 1986